Emerging Immunotherapies & Novel Therapeutics in Endometrial Cancer

A GOG Foundation, Inc. Independent Satellite Symposia

Wednesday, August 11, 2021
GOG CONFIDENTIALITY NOTICE

- This presentation is the property of The GOG Foundation, Inc. (“GOG”) and/or our Sponsors and is strictly confidential. It contains information intended only for the person to whom it is transmitted and is not to be shared with any third party without the prior written consent of the GOG General Counsel.
- With receipt of this information, recipient acknowledges and agrees that: (i) this document is not to be distributed; (ii) the recipient will not copy, duplicate, photograph, reproduce, divulge, or distribute this confidential information, in whole or in part, without the express written consent of the GOG General Counsel; and (iii) all of the information herein will be treated as confidential material with no less care than that afforded to its own confidential material.
GOG FACULTY DISCLOSURE INFORMATION

Virtual Symposium, “Emerging Immunotherapies & Novel Therapeutics in Endometrial Cancer”

AUGUST 11, 2021

In accordance with the ACCME Accreditation Criteria, The GOG Foundation, Inc., as the accredited provider of this activity, must ensure that anyone in a position to control the content of the educational activity has disclosed all relevant financial relationships with any ineligible company *(formally known as commercial interests). All Committee/Planning/Faculty members were required to disclose all financial relationships and speakers were required to disclose any financial relationship as it pertains to the content of the presentations.

The ACCME does not consider providers of clinical service directly to patients to be an ineligible company. “Relevant” financial relationships are financial transactions (in any amount) occurring within the past 24 months that may create a conflict of interest.

Please note we have advised the speakers that it is their responsibility to disclose at the start of their presentation if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage. The requirement for disclosure is not intended to imply any impropriety of such relationships, but simply to identify such relationships through full disclosure, and to allow the audience to form its own judgments regarding the presentation.

All of the relevant financial relationships listed for these individuals have been mitigated. However, if you perceive a bias during a session, please report the circumstances on the session evaluation form.

NEW TERM *An “ineligible company”* is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
<table>
<thead>
<tr>
<th>NAME</th>
<th>Individual's Role(s) in Activity</th>
<th>Nothing To Disclose</th>
<th>DISCLOSURE &lt;company &amp; role&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Angeles Alvarez Secord</td>
<td>Speaker</td>
<td></td>
<td>Advisory Board: Myriad</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Contracted clinical trial research:</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>AbbVie, AstraZeneca, Boehringer,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Clovis, Eisai, immuteq. Ltd, Merck,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>National Cancer Trial Network, Oncoquest,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>PharmaMar, Roche/Genentech, Seagen inc.,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Tesaro/GSK, VBL Therapeutics</td>
</tr>
<tr>
<td>Bradley J. Monk, MD</td>
<td>Speaker</td>
<td></td>
<td>Honoraria: Consulting/Speaker: Aganus,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Akaso, AstraZeneca, Aravive, Clovis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Easai, Elevar, Genmab/Seattle Genetics,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GOG Foundation, Gradalis, Iovance,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Karyopharm, Merck, McKesson, Mersana,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Myriad, Novocure, Pfizer, Roche/Genentech,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sorrento, Tesaro/GSK, VBL</td>
</tr>
<tr>
<td>Tashanna Myers, MD</td>
<td>Speaker</td>
<td>x</td>
<td>Consultant: Abbvie, AstraZeneca, Clovis,</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>GSK, Genentech, Merck, Myriad</td>
</tr>
<tr>
<td>Brian Slomovitz, MD</td>
<td>Speaker</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Michelle Small</td>
<td>Staff</td>
<td>x</td>
<td></td>
</tr>
<tr>
<td>Jill Reese</td>
<td>Staff</td>
<td>x</td>
<td></td>
</tr>
</tbody>
</table>
In support of improving patient care, this activity has been planned and implemented by The GOG Foundation, Inc. (GOG).

Accreditation Statement
The GOG Foundation, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide Continuing Medical Education for physicians.

AMA PRA Category 1 Credits™
The GOG Foundation, Inc. designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation
There are no fees for participating in and receiving CME credit for this activity. During the accredited period, participants must: 1) read the educational objectives and faculty disclosures; 2) attend the educational activity; 3) complete the pre- and post-test and evaluation.

Participants who complete the educational activity, pre- and post-test, and evaluation will receive a certificate of credit.
AGENDA

6:00 pm – 6:07 pm  Welcome & Introduction
Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital Phoenix, Arizona, USA

6:07 pm – 6:25 pm  The Current Therapeutic Landscape in Endometrial Cancer
Tashanna Myers, MD, Division Chief Gynecologic Oncology, University of Massachusetts School of Medicine- Baystate, Springfield, Massachusetts, USA

6:25 pm – 6:43 pm  Emerging Therapies and Clinical Trials
Brian Slomovitz, MD, Mount Sinai Medical Center, Miami Beach, Florida, USA

6:43 pm – 7:01 pm  Research to Practice – Understanding Treatment Options for Your Patient
Angeles Alvarez Secord, MD, MHSc, Director of Gynecologic Oncology Clinical Trials, Duke Cancer Center Institute, Durham, North Carolina, USA

7:01 pm – 7:11 pm  Treatment and Toxicity
Bradley J. Monk, MD, Arizona Oncology (US Oncology Network), University of Arizona College of Medicine, Creighton University School of Medicine at St. Joseph’s Hospital Phoenix, Arizona, USA

7:11 pm – 7:15 pm  Wrap Up, Panel Discussion and Final Word
All Session Faculty
POLLING QUESTION 1

What region of the world are you from?

a) U.S. – West Coast
b) U.S. – Midwest
c) U.S. – Southwest
d) U.S. – East Coast
e) Europe
f) Asia
g) Other
POLLING QUESTION 2

How many years have you been in practice?

a) 1 – 5 Years
b) 6 – 10 Years
c) 10 – 15 Years
d) 15 – 25 Years
e) 25+ Years
POLLING QUESTION 3

What is your specialty?

a) Fellow
b) Attending
c) Practicing
d) Senior/Retired
e) Industry
f) Nurse/PA
POLLING QUESTION 4

Does your site participate in GOG Trials?
   a) No
   b) Yes, Enroll > 3 trials
   c) Yes, Enroll < 3 trials
POLLING QUESTION 5

Please select all that are correct:
Randomized Phase III enroll to alkermers, Keynote 775 Trial Shows the following:
   a) Improves PFS
   b) Improved in OS
   c) Improvement in PRO (Patient Reported Outcomes)
   d) Improved Tolerability